Nereide Stela Santos-Magalhães

Nereide Stela Santos-Magalhães


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
NSNereide Stela Santos-Magalhães
Nereide Stela Santos-Magalhães
Vanessa Carla Furtado MosqueiraVanessa Carla Furtado Mosqueira
Vanessa Carla Furtado Mosqueira

1 January 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LMLina Clara Gayoso e Ibiapina Moreno
Lina Clara Gayoso e Ibiapina Moreno
EPElena Puerta
Elena Puerta
JSJosé Eduardo Suárez-Santiago
José Eduardo Suárez-Santiago
NSNereide Stela Santos-Magalhães
Nereide Stela Santos-Magalhães
MRMaria J. Ramirez
Maria J. Ramirez
Juan M. IracheJuan M. Irache
Juan M. Irache

1 February 2013 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
Pabyton Gonçalves CadenaPabyton Gonçalves Cadena
Pabyton Gonçalves Cadena
MPMarcela A. Pereira
Marcela A. Pereira
RCRafaela B.S. Cordeiro
Rafaela B.S. Cordeiro
Isabella Macário Ferro CavalcantiIsabella Macário Ferro Cavalcanti
Isabella Macário Ferro Cavalcanti
BNBenício Barros Neto
Benício Barros Neto
NSNereide Stela Santos-Magalhães
Nereide Stela Santos-Magalhães

1 September 2005 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
MMMargareth Mayer
Margareth Mayer
MOMary A. O'NEill
Mary A. O'NEill
KMKaren E. Murray
Karen E. Murray
NSNereide Stela Santos-Magalhães
Nereide Stela Santos-Magalhães
ACAna Maria A. Carneiro-Leão
Ana Maria A. Carneiro-Leão
VAVirginia C. L. Appleyard
Virginia C. L. Appleyard
The majority of human tumors bear inactive p53 or cellular factors that down-regulate the expression and activity of the p53 network. Therefore, finding therapies that are effective in such tumors is of great interest. Usnic acid, a normal component of lichens, showed activity against the wild-type p53 breast cancer cell line MCF7 as well as the non-functional p53 breast cancer cell line MDA-MB-231 and the lung cancer cell line H1299 (null for p53). In MCF7 cells treated with usnic acid, although there was an accumulation of p53 and p21 proteins, the transcriptional activity of p53 remained unaffected. We also found that there was no phosphorylation of p53 at Ser15 after treatment of MCF7 cells with usnic acid, suggesting that the oxidative stress and disruption of the normal metabolic processes of cells triggered by usnic acid does not involve DNA damage. The property of usnic acid as a non-genotoxic anti-cancer agent that works in a p53-independent manner makes it a potential candidate for novel cancer therapy.

1 September 2003 in Journal of Controlled Release
Verified
Journal Article
Closed access
JRJ.S Rodrigues
J.S Rodrigues
NSNereide Stela Santos-Magalhães
Nereide Stela Santos-Magalhães
LCL.C.B.B Coelho
L.C.B.B Coelho
PCPatrick Couvreur
Patrick Couvreur
GPG Ponchel
G Ponchel
Ruxandra GrefRuxandra Gref
Ruxandra Gref

1 October 2006 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
NSNoemia Pereira da Silva Santos
Noemia Pereira da Silva Santos
SNSilene Carneiro Nascimento
Silene Carneiro Nascimento
MWMarcela Silvestre Outtes Wanderley
Marcela Silvestre Outtes Wanderley
NPNicodemos Teles Pontes-Filho
Nicodemos Teles Pontes-Filho
JSJosé Figueiredo da Silva
José Figueiredo da Silva
NSNereide Stela Santos-Magalhães
Nereide Stela Santos-Magalhães